All Stories

  1. The structure of a C. neoformans polysaccharide motif recognized by protective antibodies: A combined NMR and MD study
  2. The hypothermic nature of fungi
  3. Similar evolutionary trajectories in an environmental Cryptococcus neoformans isolate after human and murine infection
  4. Bet-hedging antimicrobial strategies in macrophage phagosome acidification drive the dynamics of Cryptococcus neoformans intracellular escape mechanisms
  5. On the relationship between Pathogenic Potential and Infective Inoculum
  6. Glyphosate inhibits melanization and increases susceptibility to infection in insects
  7. A glycan FRET assay for detection and characterization of catalytic antibodies to the Cryptococcus neoformans capsule
  8. Updating the fungal infection-mammalian selection hypothesis at the end of the Cretaceous Period
  9. The intracellular pathogen concept
  10. The Buoyancy ofCryptococcus neoformansIs Affected by Capsule Size
  11. The Capsule of Cryptococcus neoformans Modulates Phagosomal pH through Its Acid-Base Properties
  12. In Fungal Intracellular Pathogenesis, Form Determines Fate
  13. Opsonin-free, real-time imaging of Cryptococcus neoformans capsule during budding
  14. Analysis and Correction of Inappropriate Image Duplication: the Molecular and Cellular Biology Experience
  15. Extracellular vesicles and vesicle-free secretome of the protozoa Acanthamoeba castellanii under homeostasis and nutritional stress and their damaging potential to host cells
  16. Conservation of Intracellular Pathogenic Strategy among Distantly Related Cryptococcal Species
  17. Using Preprints for Journal Clubs
  18. The Capsule of Cryptococcus neoformans
  19. Graduate Biomedical Science Education Needs a New Philosophy
  20. Erratum for Schloss et al., “Support Science by Publishing in Scientific Society Journals”
  21. What Is a Host? Attributes of Individual Susceptibility
  22. Support Science by Publishing in Scientific Society Journals
  23. Antibody-Mediated Catalysis in Infection and Immunity
  24. The mBio American Academy of Microbiology Submission Track in 2017
  25. Physiological Differences in Cryptococcus neoformans Strains In Vitro versus In Vivo and Their Effects on Antifungal Susceptibility
  26. Rigorous Science: a How-To Guide
  27. A Framework for Improving the Quality of Research in the Biological Sciences
  28. Moonshot Science—Risks and Benefits
  29. Reply to “Funding by Lottery: Political Problems and Research Opportunities”
  30. ASM Journals Eliminate Impact Factor Information from Journal Websites
  31. ASM Journals Eliminate Impact Factor Information from Journal Websites
  32. ASM Journals Eliminate Impact Factor Information from Journal Websites
  33. ASM Journals Eliminate Impact Factor Information from Journal Websites
  34. ASM Journals Eliminate Impact Factor Information from Journal Websites
  35. ASM Journals Eliminate Impact Factor Information from Journal Websites
  36. ASM Journals Eliminate Impact Factor Information from Journal Websites
  37. ASM Journals Eliminate Impact Factor Information from Journal Websites
  38. The Holobiont/Hologenome Concept Series
  39. Revolutionary Science
  40. Impacted Science: Impact Is Not Importance
  41. (A)Historical Science
  42. Field Science—the Nature and Utility of Scientific Fields
  43. Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi
  44. The Justification for the Academy Track in mBio
  45. Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research
  46. Role of Cln1 during melanization of Cryptococcus neoformans
  47. Dual-Use Research of Concern (DURC) Review at American Society for Microbiology Journals
  48. Achieving Speaker Gender Equity at the American Society for Microbiology General Meeting
  49. Biofilm Formation by Cryptococcus neoformans
  50. Competitive Science: Is Competition Ruining Science?
  51. Lipid Biosynthetic Genes Affect Candida albicans Extracellular Vesicle Morphology, Cargo, and Immunostimulatory Properties
  52. Lymphatic Aging
  53. The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases
  54. A New Synthesis for Dual Use Research of Concern
  55. Solid-state NMR Reveals the Carbon-based Molecular Architecture of Cryptococcus neoformans Fungal Eumelanins in the Cell Wall
  56. Variable Region Identical IgA and IgE to Cryptococcus neoformans Capsular Polysaccharide Manifest Specificity Differences
  57. The Importance of Virology at a Time of Great Need and Great Jeopardy
  58. Distribution and impact of yeast thermal tolerance permissive for mammalian infection
  59. Release of mycobacterial antigens
  60. B cells and antibodies in the defense againstMycobacterium tuberculosisinfection
  61. Competitive Science: Is Competition Ruining Science?
  62. Radiolabeled Antibodies for Therapy of Infectious Diseases
  63. What is infectiveness and how is it involved in infection and immunity?
  64. mBio Addresses the Pause in Gain-of-Function (GOF) Experiments Involving Pathogens with Pandemic Potential (PPP)
  65. Falling down the Rabbit Hole: aTRIP Toward Lexiconic Precision in the “Gain-of-Function” Debate
  66. Vagueness and Costs of the Pause on Gain-of-Function (GOF) Experiments on Pathogens with Pandemic Potential, Including Influenza Virus
  67. Microbiology: Ditch the term pathogen
  68. Challenges posed by extracellular vesicles from eukaryotic microbes
  69. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection
  70. Compositional and immunobiological analyses of extracellular vesicles released byCandida albicans
  71. What Is a Host? Incorporating the Microbiota into the Damage-Response Framework: TABLE 1
  72. Acknowledgment of Invited Editors
  73. Functional Improvement of Regulatory T Cells from Rheumatoid Arthritis Subjects Induced by Capsular Polysaccharide Glucuronoxylomannogalactan
  74. Visualizing Non-lytic Exocytosis of Cryptococcus neoformans from Macrophages Using Digital Light Microscopy
  75. Financial costs and personal consequences of research misconduct resulting in retracted publications
  76. Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae
  77. A Role for LHC1 in Higher Order Structure and Complement Binding of the Cryptococcus neoformans Capsule
  78. Pathogenicity of Cryptococcus neoformans: an Evolutionary Perspective
  79. Pigment Production on L-Tryptophan Medium by Cryptococcus gattii and Cryptococcus neoformans
  80. Cryptococcus neoformans: Latency and Disease
  81. The History of Cryptococcus and Cryptococcosis
  82. Cryptococcosis
  83. Acquired Humoral Immunity to Cryptococcus neoformans
  84. Acquired Immunity against Fungi
  85. Vaccines and Antibody Therapies from Cryptococcus neoformans to Melanoma
  86. Melanin: Structure, Function, and Biosynthesis in Cryptococcus
  87. The Architecture and Antigenic Composition of the Polysaccharide Capsule
  88. Cryptococcus neoformans: Nonvertebrate Hosts and the Emergence of Virulence
  89. Acquired Antibody-Mediated Immunity to Fungi
  90. Specialized Science
  91. Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct
  92. Platelet-activating Factor Contributes to Bacillus anthracis Lethal Toxin-associated Damage
  93. The Intracellular Life ofCryptococcus neoformans
  94. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity
  95. Demonstration of a common indole-based aromatic core in natural and synthetic eumelanins by solid-state NMR
  96. The Tools for Virulence of Cryptococcus neoformans
  97. Isolation and identification of membrane vesicle-associated proteins in Gram-positive bacteria and mycobacteria
  98. Insights into fungal pathogenesis from the iatrogenic epidemic of Exserohilum rostratum fungal meningitis
  99. Global structures of IgG isotypes expressing identical variable regions
  100. The constant region affects antigen binding of antibodies to DNA by altering secondary structure
  101. Binding of the wheat germ lectin to Cryptococcus neoformans chitooligomers affects multiple mechanisms required for fungal pathogenesis
  102. Phylogenetics and Evolution of Virulence in the Kingdom Fungi
  103. Radioimmunotherapy ofCryptococcus neoformansspares bystander mammalian cells
  104. Progress in understanding fungal pathogenesis
  105. Correction: Why Has the Number of Scientific Retractions Increased?
  106. Why Has the Number of Scientific Retractions Increased?
  107. Immunogenicity of mycobacterial vesicles in humans: Identification of a new tuberculosis antibody biomarker
  108. The Role of Host Gender in the Pathogenesis of Cryptococcus neoformans Infections
  109. Why We Cheat
  110. Allergen1regulates polysaccharide structure inCryptococcus neoformans
  111. Disease-Enhancing Antibodies Improve the Efficacy of Bacterial Toxin-Neutralizing Antibodies
  112. Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma
  113. Antibody-Mediated Immunity against Tuberculosis: Implications for Vaccine Development
  114. Exserohilum rostratum fungal meningitis associated with methylprednisolone injections
  115. Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy
  116. The Microbial Capsular Polysaccharide Galactoxylomannan Inhibits IL-17A Production in Circulating T Cells from Rheumatoid Arthritis Patients
  117. Elucidating the Structural Framework of Synthetic and Fungal Melanins by Solid-State NMR
  118. The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies
  119. A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan
  120. Compton Scattering by Internal Shields Based on Melanin-Containing Mushrooms Provides Protection of Gastrointestinal Tract from Ionizing Radiation
  121. Fungi and the Rise of Mammals
  122. Using Solid-State NMR To Monitor the Molecular Consequences of Cryptococcus neoformans Melanization with Different Catecholamine Precursors
  123. Recent progress in vaccines against fungal diseases
  124. Winner Takes All
  125. Monoclonal Antibodies and Toxins—A Perspective on Function and Isotype
  126. Quorum sensing in fungi – a review
  127. Immunoglobulins in Defense, Pathogenesis, and Therapy of Fungal Diseases
  128. Mouse models for the study of fungal pneumonia
  129. The future of biological warfare
  130. Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication
  131. Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding
  132. Serum albumin disrupts Cryptococcus neoformans and Bacillus anthracis extracellular vesicles
  133. Fungal Melanins Differ in Planar Stacking Distances
  134. Adaptations of avian flu virus are a cause for concern
  135. Capsules from Pathogenic and Non-Pathogenic Cryptococcus spp. Manifest Significant Differences in Structure and Ability to Protect against Phagocytic Cells
  136. Reforming Science
  137. A Global Forum for Clinical Microbiologists and Immunologists
  138. Q&A: What is a pathogen? A question that begs the point
  139. Recent Advances on Model Hosts
  140. Probing the Molecular Architecture and Assembly of Synthetic and Fungal Melanins with Solid-State NMR
  141. In Vitro Measurement of Phagocytosis and Killing of Cryptococcus neoformans by Macrophages
  142. Reforming Science: Structural Reforms
  143. A new synthesis for antibody-mediated immunity
  144. Synthesis and assembly of fungal melanin
  145. Vesicular transport systems in fungi
  146. Protection of the Melanized Fungus Cryptococcus Neoformans From Lethal Dose Gamma Irradiation Involves Changes in Melanin's Chemical Structure and Paramagnetic Properties
  147. Methylxanthine Inhibit Fungal Chitinases and Exhibit Antifungal Activity
  148. Amoeba Provide Insight into the Origin of Virulence in Pathogenic Fungi
  149. Ten Challenges on Cryptococcus and Cryptococcosis
  150. Protection of Melanized Cryptococcus neoformans from Lethal Dose Gamma Irradiation Involves Changes in Melanin's Chemical Structure and Paramagnetism
  151. Cryptococcus neoformans Capsular Enlargement and Cellular Gigantism during Galleria mellonella Infection
  152. Gamma radiation interacts with melanin to alter its oxidation–reduction potential and results in electric current production
  153. Cryptococcus neoformansgalactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy
  154. Microbial Virulence as an Emergent Property: Consequences and Opportunities
  155. The effect of L-DOPA onCryptococcus neoformansgrowth and gene expression
  156. Phospholipids Trigger Cryptococcus neoformans Capsular Enlargement during Interactions with Amoebae and Macrophages
  157. Role for Golgi reassembly and stacking protein (GRASP) in polysaccharide secretion and fungal virulence
  158. mBio’s First Birthday
  159. Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice
  160. Evaluation of Cryptococcus neoformans galactoxylomannan–protein conjugate as vaccine candidate against murine cryptococcosis
  161. Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity
  162. Melanin and Resistance to Ionizing Radiation in Fungi
  163. Fungal Polysaccharides: Biological Activity Beyond the Usual Structural Properties
  164. Biophysical Methods for the Study of Microbial Surfaces
  165. Phenylalanine hydroxylase (PAH) from the lower eukaryote Leishmania major
  166. Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
  167. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line
  168. Melanin-Covered Nanoparticles for Protection of Bone Marrow During Radiation Therapy of Cancer
  169. Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6
  170. Cryptococcus
  171. Biogenesis of extracellular vesicles in yeast
  172. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule ofCryptococcus neoformans
  173. Reproducible Science
  174. Role of CD45 Signaling Pathway in Galactoxylomannan-Induced T Cell Damage
  175. An insight into the antifungal pipeline: selected new molecules and beyond
  176. Radioimmunotherapy Is More Effective than Antifungal Treatment in Experimental Cryptococcal Infection
  177. Paramecium species ingest and kill the cells of the human pathogenic fungus Cryptococcus neoformans
  178. Proteasome Inhibitors Prevent Caspase-1-Mediated Disease in Rodents Challenged with Anthrax Lethal Toxin
  179. Intracellular cryptococci suppress Fc-mediated cyclin D1 elevation
  180. Correction: Fungal Cell Gigantism during Mammalian Infection
  181. Fungal Cell Gigantism during Mammalian Infection
  182. Characterization of Yeast Extracellular Vesicles: Evidence for the Participation of Different Pathways of Cellular Traffic in Vesicle Biogenesis
  183. Destruction of Microbial Collections in Response to Select Agent and Toxin List Regulations
  184. ASM Launches mBio
  185. Cryptococci at the brain gate: break and enter or use a Trojan horse?
  186. Abstract 5344: The contribution of unlabeled antibodies to intracellular antigens to efficacy of radioimmunotherapy in experimental metastatic melanoma and cervical cancer
  187. Circular Dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure☆
  188. Hark back: Passive immunotherapy for influenza and other serious infections
  189. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism
  190. The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of 188Re-labeled anti-E6 C1P5 antibody in cervical cancer in mice
  191. The use of chitosan to damage Cryptococcus neoformans biofilms
  192. Microbial threat lists: obstacles in the quest for biosecurity?
  193. Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo
  194. Natural Melanin Produced in Fungi Protects Cells from High Dose Ionizing Radiation: An EPR Study
  195. Monoclonal antibody-based therapies for microbial diseases
  196. The still obscure attributes of cryptococcal glucuronoxylomannan
  197. Cryptococcus neoformans cryoultramicrotomy and vesicle fractionation reveals an intimate association between membrane lipids and glucuronoxylomannan
  198. Vertebrate Endothermy Restricts Most Fungi as Potential Pathogens
  199. Physico-Chemical Evaluation of Rationally Designed Melanins as Novel Nature-Inspired Radioprotectors
  200. The “Nuclearization” of Biology Is a Threat to Health and Security
  201. The Elastic Properties of the Cryptococcus neoformans Capsule
  202. Virulence factors and their mechanisms of action: the view from a damage–response framework
  203. Resistance of melanized yeast cells of Paracoccidioides brasiliensis to antimicrobial oxidants and inhibition of phagocytosis using carbohydrates and monoclonal antibody to CD18
  204. The case for pathogen-specific therapy
  205. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies
  206. Structural and functional properties of the Trichosporon asahii glucuronoxylomannan
  207. Vesicular transport across the fungal cell wall
  208. Radioimmunotherapy of Infectious Diseases
  209. Sec6-dependent sorting of fungal extracellular exosomes and laccase ofCryptococcus neoformans
  210. Is Peer Review Censorship?
  211. The still obscure attributes of cryptococcal glucuronoxylomannan
  212. The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes
  213. Chapter 4 The Capsule of the Fungal Pathogen Cryptococcus neoformans
  214. Intracellular pathogenic bacteria and fungi — a case of convergent evolution?
  215. Ionizing radiation: how fungi cope, adapt, and exploit with the help of melanin
  216. Biodefense Research: A Win-Win Challenge
  217. Evolution of Intracellular Pathogens
  218. Capsule enlargement inCryptococcus neoformansconfers resistance to oxidative stress suggesting a mechanism for intracellular survival
  219. In vitro evaluation, biodistribution and scintigraphic imaging in mice of radiolabeled anthrax toxins
  220. The Outcome of Phagocytic Cell Division with Infectious Cargo Depends on Single Phagosome Formation
  221. Fungal killing by mammalian phagocytic cells
  222. Antibody action after phagocytosis promotesCryptococcus neoformansandCryptococcus gattiimacrophage exocytosis with biofilm-like microcolony formation
  223. Vesicular transport inHistoplasma capsulatum: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes
  224. A role for vesicular transport of macromolecules across cell walls in fungal pathogenesis
  225. Finite-Element Model of Interaction between Fungal Polysaccharide and Monoclonal Antibody in the Capsule of Cryptococcus neoformans
  226. Characterization of Phenotypic Switching in Cryptococcus neoformans Biofilms
  227. Following Fungal Melanin Biosynthesis with Solid-State NMR: Biopolymer Molecular Structures and Possible Connections to Cell-Wall Polysaccharides †
  228. Chemosorption of radiometals of interest to nuclear medicine by synthetic melanins
  229. The immunoglobulin constant region contributes to affinity and specificity
  230. Analysis of epitope information related toBacillus anthracisandClostridium botulinum
  231. Passive administration of monoclonal antibodies to Anthrolysin O prolong survival in mice lethally infected with Bacillus anthracis
  232. Pulmonary cryptococcosis induces chitinase in the rat
  233. Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1
  234. The radioprotective properties of fungal melanin are a function of its chemical composition, stable radical presence and spatial arrangement
  235. Exchanging Murine and Human Immunoglobulin Constant Chains Affects the Kinetics and Thermodynamics of Antigen Binding and Chimeric Antibody Autoreactivity
  236. Determinants of virulence in the pathogenic fungi
  237. New insights on the pathogenesis of invasive Cryptococcus neoformans infection
  238. Monoclonal antibodies to Mycobacterium tuberculosis CDC 1551 reveal subcellular localization of MPT51
  239. Phage Display Library Derived Peptides that Bind to Human Tumor Melanin as Potential Vehicles for Targeted Radionuclide Therapy of Metastatic Melanoma
  240. Treating Cancer as an Infectious Disease—Viral Antigens as Novel Targets for Treatment and Potential Prevention of Tumors of Viral Etiology
  241. Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to metastatic melanoma tumors with wide range of melanin concentrations
  242. Caspofungin reduces the incidence of fungal contamination in cell culture
  243. Fungal Infections (In Humans)
  244. Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches
  245. Targeting the Virus with Radioimmunotherapy in Virus-Associated Cancers
  246. Coccidioides posadasii produces melanin in vitro and during infection
  247. SEROLOGIC EVIDENCE FOR REGIONAL DIFFERENCES IN PEDIATRIC CRYPTOCOCCAL INFECTION
  248. Ionizing Radiation Changes the Electronic Properties of Melanin and Enhances the Growth of Melanized Fungi
  249. Targeting host cells harbouring viruses with radiolabeled antibodies
  250. The volume and hydration of the Cryptococcus neoformans polysaccharide capsule
  251. Cryptotrichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar
  252. Pathogenesis of Cryptococcus neoformans
  253. Exploiting Amoeboid and Non-Vertebrate Animal Model Systems to Study the Virulence of Human Pathogenic Fungi
  254. Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages
  255. DEVELOPING A MATHEMATICAL MODEL OF PHAGOCYTOSIS: A LEARNING PROCESS
  256. Update : Renaissance of Targeting Molecules for Melanoma
  257. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance
  258. Targeted Killing of Virally Infected Cells by Radiolabeled Antibodies to Viral Proteins
  259. Phagosome Extrusion and Host-Cell Survival after Cryptococcus neoformans Phagocytosis by Macrophages
  260. The capsular dynamics of Cryptococcus neoformans
  261. Characterization of a flocculation-like phenotype in Cryptococcus neoformans and its effects on pathogenesis
  262. Immunomodulators as an antimicrobial tool
  263. Efficacy of voriconazole in experimental Cryptococcus neoformans infection
  264. Specific Antibody to Cryptococcus neoformans Glucurunoxylomannan Antagonizes Antifungal Drug Action against Cryptococcal Biofilms In Vitro
  265. Equatorial ring-like channels in the Cryptococcus neoformans polysaccharide capsule
  266. Interaction of Radiolabeled Antibodies with Fungal Cells and Components of the Immune System In Vitro and during Radioimmunotherapy for Experimental Fungal Infection
  267. Enhanced Allergic Inflammation and Airway Responsiveness in Rats with Chronic Cryptococcus neoformans Infection: Potential Role for Fungal Pulmonary Infection in the Pathogenesis of Asthma
  268. Radiolabeled Melanin-Binding Peptides Are Safe and Effective in Treatment of Human Pigmented Melanoma in a Mouse Model of Disease
  269. Structural and functional characterization of glycosylation in an immunoglobulin G1 to Cryptococcus neoformans glucuronoxylomannan
  270. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8
  271. Melanization affects susceptibility of Cryptococcus neoformans to heat and cold1
  272. The weapon potential of human pathogenic fungi
  273. Polysaccharide-containing conjugate vaccines for fungal diseases
  274. A Reappraisal of Humoral Immunity Based on Mechanisms of Antibody‐Mediated Protection Against Intracellular Pathogens
  275. The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding
  276. Melanin in the dimorphic fungal pathogen Paracoccidioides brasiliensis: effects on phagocytosis, intracellular resistance and drug susceptibility
  277. Comparative analysis of Cryptococcus neoformans acid-resistant particles generated from pigmented cells grown in different laccase substrates
  278. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases
  279. The potential of antibody-mediated immunity in the defence against biological weapons
  280. Melanin as a potential target for radionuclide therapy of metastatic melanoma
  281. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures
  282. A point mutation in the Ch3 domain of human IgG3 inhibits antibody secretion without affecting antigen specificity
  283. Prof. Dr. Ricardo Arturo Ronderos (1928-1995)
  284. Microstructure of Cell Wall-Associated Melanin in the Human Pathogenic Fungus Cryptococcus neoformans †
  285. Fungal virulence, vertebrate endothermy, and dinosaur extinction: is there a connection?
  286. Investigation of Fungal Deterioration of Synthetic Paint Binders Using Vibrational Spectroscopic Techniques
  287. Coping with Multiple Virulence Factors: Which Is Most Important?
  288. Role of Antibody-Mediated Immunity in Host Defense against Mycobacterium tuberculosis
  289. Prospects of vaccines for medically important fungi Feasibility and prospects for a vaccine to prevent cryptococcosis
  290. Glucuronoxylomannan, a Microbial Compound, Regulates Expression of Costimulatory Molecules and Production of Cytokines in Macrophages
  291. Blastomyces dermatitidis produces melanin in vitro and during infection
  292. Passive antibody therapy for infectious diseases
  293. The methodology for determining the efficacy of antibody-mediated immunity
  294. The weapon potential of a microbe
  295. Response to Fehr and Ochsenbein: ‘Good’, ‘bad’ and ‘neutral’ antibodies depend on the host–microbe interaction
  296. Experimental modulation of capsule size in Cryptococcus neoformans
  297. Cryptococcus neoformans var. gattii can exploit Acanthamoeba castellanii for growth
  298. Serotype distribution of Cryptococcus neoformans in patients in a tertiary care center in India1
  299. A ten-year-old boy with a pulmonary nodule secondary to Cryptococcus neoformans: case report and review of the literature
  300. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum
  301. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum
  302. The damage-response framework of microbial pathogenesis
  303. ‘Anti-virulence’ genes – further muddling the lexicon?
  304. Antibody-mediated regulation of cellular immunity and the inflammatory response
  305. Phenotypic switching of Cryptococcus neoformans can influence the outcome of the human immune response
  306. ‘Ready made’ virulence and ‘dual use’ virulence factors in pathogenic environmental fungi — the Cryptococcus neoformans paradigm
  307. Unlocking the Molecular Structure of Fungal Melanin Using 13 C Biosynthetic Labeling and Solid-State NMR †
  308. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirectC3-mediated interactions
  309. The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans
  310. Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis
  311. Microbial virulence results from the interaction between host and microorganism
  312. The contribution of melanin to microbial pathogenesis
  313. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils
  314. Site-specific characterization of the N-linked oligosaccharides of a murine immunoglobulin M by high-performance liquid chromatography/electrospray mass spectrometry
  315. Cryptococcosis
  316. Phenotypic switching in Cryptococcus neoformans
  317. The meaning of microbial exposure, infection, colonisation, and disease in clinical practice
  318. Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons
  319. Induced humoral immunity and vaccination against major human fungal pathogens
  320. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) Are Involved in Complement-Independent Antibody-Mediated Phagocytosis of Cryptococcus neoformans
  321. Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells
  322. Antibodies for defense against biological attack
  323. Identification and characterization of the Cryptococcus neoformans phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity
  324. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection
  325. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection
  326. Adjunctive Immune Therapy for Fungal Infections
  327. Cryptococcus neoformans: intracellular or extracellular?
  328. Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection
  329. Host‐Pathogen Interactions: The Attributes of Virulence
  330. Intracellular parasitism of macrophages by Cryptococcus neoformans
  331. Immunity to Fungi
  332. Fungal Infections in Humans
  333. Glyphosate Inhibits Melanization of Cryptococcus neoformans and Prolongs Survival of Mice after Systemic Infection
  334. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans
  335. The Effect of the Echinocandin Analogue Caspofungin on Cell Wall Glucan Synthesis by Cryptococcus neoformans
  336. Normalization of anti-cryptococcal activity and interleukin-12 production after highly active antiretroviral therapy
  337. Human and murine immunoglobulin expression vector cassettes
  338. Isolation and serological analyses of fungal melanins
  339. Host–microbe interactions: fungi
  340. Melanin and virulence in Cryptococcus neoformans
  341. Melanisation of Cryptococcus neoformans in human brain tissue
  342. Neutrophils from Patients with Advanced Human Immunodeficiency Virus Infection Have Impaired Complement Receptor Function and Preserved Fcγ Receptor Function
  343. Passive Antibody Therapies: Progress and Continuing Challenges
  344. Cryptococcus neoformans by Casadevall, Arturo & Perfect, John R. (1998) ASM Press, Washington, DC. Hardcover. 542 pp. $89.95. (ASM Member price: $79.95).
  345. Monoclonal Antibody–Mediated Toxicity in Cryptococcus neoformans Infection: Mechanism and Relationship to Antibody Isotype
  346. Labeling of Proteins with [35S]Methionine and/or [35S]Cysteine in the Absence of Cells
  347. Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans
  348. Separated at Birth
  349. Serial Isolates of Cryptococcus neoformans from Patients with AIDS Differ in Virulence for Mice
  350. Cryptococcus neoformans
  351. Effect of Antibody to Capsular Polysaccharide on Eosinophilic Pneumonia in Murine Infection with Cryptococcus neoformans
  352. Effect of Immune Mechanisms on the Pharmacokinetics and Organ Distribution of Cryptococcal Polysaccharide
  353. Response from Casadevall
  354. Antibody-mediated protection against intracellular pathogens
  355. Antibody-based therapies as anti-infective agents
  356. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes
  357. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes
  358. The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes
  359. Reply
  360. PERSISTENT VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM BACTEREMIA
  361. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy
  362. Antibody-Based Therapies for Emerging Infectious Diseases
  363. Cryptococcus neoformans: Paradigm for the Role of Antibody Immunity Against Fungi?
  364. Pathology of cryptococcal meningoencephalitis: Analysis of 27 patients with pathogenetic implications
  365. Reply
  366. Reply
  367. Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro
  368. Antibody immunity and Cryptococcus neoformans
  369. Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody
  370. Decreased Fluconazole Susceptibility of a Relapse Cryptococcus neoformans Isolate After Fluconazole Treatment
  371. Monoclonal antibody mediated capsular reactions (Quellung) in Cryptococcus neoformans
  372. Cryptococcus neoformans infection can elicit protective antibodies in mice
  373. Enhancement of HIV Type 1 Infectivity in Vitro by Capsular Polysaccharide of Cryptococcus neoformans and Haemophilus influenzae
  374. Reactive Nitrogen Intermediates in Human Neuropathology: An Overview
  375. The Presence of Cryptococcal Capsular Polysaccharide Increases the Sensitivity of HIV-1 Coculture in Children
  376. MU switch region deletion is associated with both T cell independent and T cell dependent responses
  377. The reply
  378. Monoclonal antibody based ELISAs for cryptococcal polysaccharide
  379. Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS
  380. URA5 gene of Cryptococcus neoformans var. gattii: evidence for a close phylogenetic relationship between C. neoformans var. gattii and C. neoformans var. neoformans.
  381. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans
  382. Thermal difference circular dichroism of Pf1 filamentous virus and effects of mercury(II), silver(I), and copper(II)
  383. Raman spectroscopy of mercury(II) binding to two filamentous viruses: Ff (fd, M13, f1) and Pf1
  384. The precursor complex of Pf3 bacteriophage
  385. Silver and mercury probing of deoxyribonucleic acid structures in the filamentous viruses fd, If1, IKe, Xf, Pf1, and Pf3
  386. DNA packing in the filamentous viruses fd, Xf, Pfl and Pf3
  387. Notes and Queries
  388. Immunotherapy for Fungal Infections
  389. Antibody-Mediated Immunity to Fungi in the Lungs
  390. Carbohydrate-Based Antifungal Vaccines
  391. The Damage-Response Framework of Microbial Pathogenesis and Infectious Diseases